Upper limb (UL) function impairment is prevalent among patients with primary progressive multiple sclerosis (PPMS) and alters a patient’s quality of life. Researchers set out to evaluate the effect of Ocrelizumab on upper limb function using the nine-hole peg test (9HPT).
The test was administered at baseline and every 12 weeks until the end of the study. The average 9HPT times for two trials of the dominant and non-dominant hands were compared, the hand with the lower baseline was termed ‘better hand’ and the hand with the higher baseline time was termed ‘both hands’.
Patients taking Ocrelizumab, compared to those taking a placebo, were able to complete the 9HPT on average 37% quicker at the end of the trial 24 weeks later.
Researchers concluded that Ocrelizumab treatment lowered the risk of progression of upper extremity disability, as measured by the 9HPT, compared with placebo in patients with PPMS.